GTx, Inc. was a pharmaceutical company that focused on the development of selective androgen receptor modulators (SARMs) for the treatment of cancer cachexia, breast cancer, and other medical conditions. The company was founded in 1997 and was headquartered in Memphis, Tennessee.
In 2019, GTx, Inc. announced its plans to dissolve and liquidate its assets after discontinuing its clinical trials for its SARMs products due to lack of efficacy and safety concerns. The company's common stock was delisted from the NASDAQ stock exchange on August 16, 2019.
GTx, Inc. was a pharmaceutical company that focused on the development of selective androgen receptor modulators (SARMs) for the treatment of cancer cachexia, breast cancer, and other medical conditions. The company was founded in 1997 and was headquartered in Memphis, Tennessee.